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Abstract
Background: We assessed the diagnostic value of standard clinical methods and combined biomarker testing
(galactomannan assay and polymerase chain reaction screening) in a prospective case–control study to detect
invasive pulmonary aspergillosis in patients with hematological malignancies and prolonged neutropenia.
Methods: In this observational study 162 biomarker analyses were performed on samples from 27 febrile neutropenic
episodes. Sera were successively screened for galactomannan antigen and for Aspergillus fumigatus specific nucleic acid
targets. Furthermore thoracic computed tomography scanning was performed along with bronchoscopy with lavage
when clinically indicated. Patients were retrospectively stratified to define a case-group with “proven” or “probable”
invasive pulmonary aspergillosis (25.93 %) and a control-group of patients with no evidence for of invasive pulmonary
aspergillosis (74.07 %). In 44.44 % of episodes fever ceased in response to antibiotic treatment (group II). Empirical
antifungal therapy was administered for episodes with persistent or relapsing fever (group I). 48.15 % of patients
died during the study period. Postmortem histology was pursued in 53.85 % of fatalities.
Results: Concordant negative galactomannan and computed tomography supported by a polymerase chain
reaction assay were shown to have the highest discriminatory power to exclude invasive pulmonary aspergillosis.
Bronchoalveolar lavage was performed in 6 cases of invasive pulmonary aspergillosis and in 15 controls. Although
bronchoalveolar lavage proved negative in 93 % of controls it did not detect IPA in 86 % of the cases. Remarkably
post mortem histology convincingly supported the presence of Aspergillus hyphae in lung tissue from a single case
which had consecutive positive polymerase chain reaction assay results but was misdiagnosed by both computed
tomography and consistently negative galactomannan assay results. For the galactomannan enzyme-immunoassay the
diagnostic odds ratio was 15.33 and for the polymerase chain reaction assay it was 28.67. According to Cohen’s kappa
our in-house polymerase chain reaction method showed a fair agreement with the galactomannan immunoassay.
Combined analysis of the results from the Aspergillus galactomannan enzyme immunoassay together with those
generated by our polymerase chain reaction assay led to no misdiagnoses in the control group.
Conclusion: The data from this pilot-study demonstrate that the consideration of standard clinical methods combined
with biomarker testing improves the capacity to make early and more accurate diagnostic decisions.
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Background
Patients suffering from hematological malignancies and
prolonged neutropenia are significantly affected by life-
threatening invasive fungal infections, particularly invasive
pulmonary aspergillosis (IPA). Despite improvements in
transplantation practices and antifungal therapy the treat-
ment of patients with IPA is still challenging [1]. Diagnosis
of IPA is difficult and delayed diagnosis contributes to the
increasing severity of IPA associated high morbidity and
mortality rates [2, 3]. Standard radiology as thoracic com-
puted tomography (CT) scan and classical mycology of
bronchoalveolar lavage (BAL) have low sensitivity and
may be no more specific than fevers of unknown origin
that are refractory to treatment with broad-spectrum anti-
biotics; especially in neutropenic patients [4, 5]. Despite
many limitations empirical antifungal therapy is regarded
as a standard treatment in these patients. The relatively
low incidence of IPA is accompanied by the risk of over
treating people thus subsequently loading them with
unnecessary drug toxicity [6]. On one hand these fever-
driven approaches use a very limited diagnostic work-up
in the need of avoiding deleterious delay in the initiation
of therapy on the other hand they may miss IPA develop-
ing in the absence of fever [7]. An alternative management
strategy could be preemptive antifungal therapy guided by
IPA associated risk factors such as mycological tools,
imaging techniques, detection of specific biomarkers by
Aspergillus galactomannan enzyme immunoassay (GM-
EIA) or sensitive polymerase chain reaction (PCR) [7, 8].
The routine use of non-culture based molecular assays
might have the potential to fill the gap between over- and
under treatment providing improved diagnosis compared
to classical methods and single assay detection [9]. The
primary aim of this non-randomized study was to assess
the applicability of our enhanced patient surveillance
strategy in routine clinical practice on our retrospectively
stratified patient population. A further aim was to esti-
mate the diagnostic utility of combined biomarker testing
from the onset of febrile neutropenia by combining serum
GM-EIA screening and facC-PCR detection. This could
show how many patients would receive a misdiagnosis
on the basis of a fever driven empirical approach without




Between June 06, 2012 and May 08, 2013, 27 febrile neu-
tropenia episodes (FNEs); 16 males with the median age
of 42.5 (range 14–75) and 11 females with the median
age of 45.5 (range; 19–66) (Table 1) were included at the
onset of febrile neutropenia. The patients had different
hematological malignancies (mainly acute leukemia) receiv-
ing stem cell transplantation and intensive chemotherapy
(neutrophil count < 0.5 × 109 cells/L; temperature > 38 °C
of febrile neutropenia recorded twice or > 38.5 °C recorded
once) in our local prospective case–control study. The
study protocol was approved by the ethics committee of
the University Hospitals of Debrecen, Hungary. Written
consent was obtained from patients and the caretakers of
the children in all of the cases. PCR testing was performed
parallel with GM-EIA and needed no ethical approval.
PCR results were sent back to clinicians however were
not taken into clinical decision making.
Search strategy
For FNE, combined biomarker testing (CBT) was com-
menced. Serum samples were prospectively screened for
the presence of genus and species specific biomarkers
galactomannan (GM) and facC genes. The results were an-
onymously evaluated [10]. Screen-ing for GM-antigenemia
Platelia Aspergillus (GM-EIA) was used on the basis of
the OD450/620 ≧ 0.5 cutoff value.
The real time PCR detection of A. fumigatus specific
DNA was based on the Streptomyces factor C ortholo-
gous gene (facC-PCR): this was most likely horizontally
transferred to a few filamentous fungi including A. fumi-
gatus as previously described [11]. Since the facC gene
that was acquired by horizontal gene transfer [12] is only
present in a few fungal species [13] and they diverged
millions of years ago, we were able to design species-
specific assays that do not cross-react even with closely
related species that carry this gene therefore the analytical
specificity is increased as compared to other assays. At the
onset of fever broad-spectrum antibiotic treatment was
administered according to the published Infectious Dis-
eases Society of America guidelines [14]. Furthermore
standard chest CT and BAL analysis were performed as
clinically indicated.
Antifungal therapy
Persistent fever, positive GM assay along with either
positive CT and/or positive BAL was considered suffi-
cient evidence to initiate broad spectrum antifungal
treatment. In the case of fever that ceased after 48 h of
antibiotic treatment, with negative CT and/or BAL re-
sults (when performed), we suggested extending the
surveillance period. These cases were monitored for the
presence of Aspergillus specific biomarkers (GM and the
facC-orthologous gene) in parallel with thorough clinical
examinations on a weekly basis.
Stratification of febrile neutropenia episodes
Cases were retrospectively stratified according to revised
European Organization for the Research and Treatment
of Cancer/Mycosis Study Group (EORTC/MSG) criteria
in order to define a case-group of “proven” or “prob-
able” IPA (7 patients) and a control-group possible IPA
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(20 patients with no EORTC/MSG evidence of invasive
aspergillosis) [10, 15].
Ascertainment bias
Ascertainment bias can potentially overestimate the
diagnostic odds ratio (DOR) for the benefit of the gold-
standard GM-EIA method. By introducing false-positives
it can erode the discriminatory power of the other diag-
nostic methods (e.g. facC-PCR).
Postmortem histology
The specificity of Aspergillus infection morphology was
critically addressed in the histological samples obtained
following autopsy. Samples were taken from the major or-
gans according to a standard protocol, but no macroscopic
signs of organ involvement were seen other than in the
lungs. Lung sampling was performed from three inde-
pendent parts of the potentially infiltrated lung paren-
chyma. Histological evaluation clearly proved the existence
of invasive fungal infection. The detailed feature of the
PAS and/or Hematoxylin and Eosin (H&E) stained hyphae
supported the Aspergillus specific PCR assay based as-
sumption of invasive aspergillosis in the lung although
other filamentous fungi may resemble Aspergillus hyphae
therefore definite identification is not possible on a mor-
phological basis.












No. of GM specimens No. of PCR specimens No. of PCR runs
Positive Negative Positive Negative Positive Negative
1 PTCL M, 18 possible 8 0 4 1 3 3 9
2 NHL M, 15 possible 14 0 7 2 5 2 19
3 OM M, 16 possible 16 0 8 1 7 3 21
4 AML M, 26 proven 18 0 7 10 1 18 15
5 OM F, 53 possible 6 1 2 0 3 0 9
6 AML M, 55 possible 4 0 2 1 1 1 5
7 AML M, 52 proven 4 2 0 2 0 3 3
8 AML F, 28 proven 6 1 2 3 0 3 4
9 MM M, 70 possible 2 0 1 0 1 0 3
10 ALL F, 27 probable 8 2 0 6 0 13 1
11 OM M, 57 possible 2 0 1 0 1 0 3
12 OM F, 66 possible 6 0 3 0 3 0 9
13 AML F, 55 probable 8 2 2 4 0 8 4
14 AML F, 46 possible 2 0 1 0 1 0 3
15 MM F, 44 possible 2 0 1 0 1 0 3
16 OM M, 56 proven 6 0 3 1 2 1 8
17 HL F, 26 possible 4 0 2 0 2 0 6
18 AML F, 50 possible 2 0 1 1 0 3 0
19 ALL M, 14 possible 4 0 2 0 2 0 6
20 AML F, 45 possible 6 0 3 0 3 0 9
21 OM M, 17 possible 6 0 3 0 3 0 9
22 OM F, 19 possible 8 0 4 3 1 3 9
23 NHL M, 57 possible 2 0 1 0 1 0 3
24 AML M, 36 possible 6 1 2 0 3 0 9
25 NHL M, 75 proven 6 2 1 1 2 1 8
26 AML M, 49 possible 4 0 2 0 2 0 6
27 OM M, 16 possible 2 0 1 0 1 0 3
Total: 162 77 85 249
aNeutrophil count < 0,5 × 109 cells/L; bUniversity of Debrecen, Institute of Internal Medicine; AML Acute Myeloid Leukemia, ALL Acute Lymphoblastic Leukemia, MM
Myeloma Multiplex, NHL Non-Hodgkin Lymphoma, PTCL Peripheral T-cell Lymphoma, OMs other malignancies, P present, A absent, NP not performed, CT thoracic
computed tomography, BAL bronchoscopy with lavage
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Serum specimens
As part of our combined biomarker testing [9] consecu-
tive serum samples (3 × 3 ml) were routinely drawn from
patients at the onset of febrile neutropenia and sent to
the Department of Medical Microbiology, Debrecen,
Hungary for GM antigen monitoring. The GM assays re-
quired 300 μl of serum samples and the rest was stored
at −20 °C. The two other intact serum tubes were for-
warded to the Department of Human Genetics, Debrecen,
Hungary for facC-PCR and opened only in our laboratory.
DNA extraction
All DNA extraction steps were performed in a class II
laminar-flow cabinet to avoid environmental contamin-
ation. Serum samples obtained from healthy volunteers
were pooled and screened for Aspergillus fumigatus nu-
cleic acid contamination prior to use as ex-traction
negative controls (2.5 ml). In order to control the effi-
ciency of the fungal nucleic acid extraction and potential
PCR inhibition the QuantiFast Pathogen PCR+IC Kit
(Qiagen, Hilden, Germany) was used to prepare extrac-
tion positive control samples (2.5 ml) containing 10 μl of
internal control DNA. 2.5 ml of serum samples obtained
from episodes were extracted along with the extraction
positive and negative controls using the High Pure Viral
Nucleic Acid Large Volume Kit (Roche Applied Science)
according to manufacturer’s instructions. The elution
volume was adjusted to 45 μl. 12 μl of eluate was used
in each PCR reactions.
FacC-PCR based real-time detection
Species specific hydrolysis assays were used that tar-
geted the facC orthologous genes present in A. fumiga-
tus [11]. A. fumigatus specific duplex TaqMan-LNA
hydrolysis assay was used targeting facC orthologous
genes (AFUA_3G14910, and AFUA_5G00540) present
in two copies (on Chr#3 and on Chr#5 respectively) in
A. fumigatus genome. The duplex assay contained
AFUA_3G14910, and AFUA_5G00540 specific primers
(0.8 μM for each) and probes (0.5 μM for each). The
primers and probe sequences were Afu3_Fw (5′-CTT
TGGCATCGCGACAGT-3′), Afu3_Rev (5′-GAGGGG
GCAGAGAGATC-3′), Afu3_probe (5′-FAM-CAGCAT
CC-DQD-3′, where DQD is dark quencher dye), Afu5_Fw
(5′-CGTCCAACAGTCATTCACCTT-3′), Afu5_Rev (5′-
ATCGCGACGGTTTACGAT-3′), Afu5_probe (5′-FAM-
CCGCCGCC-DQD-3′). Amplification was carried out on
LightCycler® 2.0 Carousel-Based platform (Roche Applied
Science). 5× LightCycler TaqMan Master (Roche Applied
Science) was used according to manufacturer’s instruc-
tions containing Uracil-DNA Glycosylase for carryover
prevention during PCR and the reaction volumes were
settled to 20 μl in glass capillaries where 12 μl of elutes
were monitored for the presence of A. fumigatus genomic
DNA. Each real-time run contained template-positive
(PCR-IC spiked with 100–1000 GE Aspergillus fumigatus
gDNA) and template-negative (PCR-NTC containing PCR
grade nuclease free water) control samples.
Data interpretation
Discriminatory power of standard methods
The discriminatory power of the CT scans combined with
either GM-EIA or with BAL were analyzed by comparison
with patient status (cases and controls), which allowed
the negative predictive values (PV−) to be calculated.
(i) Real time FacC assays. In this study triplicate
facC-PCR reactions were performed. Single positive
assay result from the triplicate reactions was used to
define a sample as PCR positive [16–18].
(ii) Galactomannan ELISA. The Platelia Aspergillus
GM-EIA (Bio-Rad Laboratories, Hungary) was used
for galactomannan screening. GM-EIA cutoff values
were determined using the OD450/620 value of
sample/OD450/620 value of control. While evaluating
single specimens any value above the OD450/620 ≧ 0.5
cutoff value was considered positive as requested for
in vitro testing. While evaluating episode GM-EIA
statuses the ratio of positive versus negative results
were analyzed. In the case of equality, an episode
was considered positive.
Statistical analysis of CBT
Along with reporting of descriptive statistics for categorical
data; median, mean, standard deviation (±SD), diagnostic
performance parameters (by doing the 2×2 contingency
tables of cases and controls) with discriminatory properties
of post-test probabilities (likelihood ratios) and accuracy
indices (DORs) were calculated with 95 % confidence
intervals (95 % CI) for GM screening (GM-EIA) and for
the nucleic acid based diagnostic method (facC-PCR)
respectively.
Biomarker measurement comparison
In this study 162 biomarker analyses from 27 febrile
neutropenic episodes with the mean number of 6 ± 4.18
specimen/episodes (range; 2–18) were performed. For
assessing sample concordance between the established
gold-standard GM-EIA screening and our in-house
facC-PCR method inter annotator agreement was calcu-
lated using the Cohen’s kappa test where values greater
than 0.8 represent an excellent agreement, values of
0.61–0.8 represent a substantial agreement, values of
0.41–0.6 a moderate agreement, values of 0.21–0.4 a fair
agreement and below 0.20 a slight agreement between
two classifiers.
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ROC analysis
To measure the diagnostic accuracy of the results from
GM-EIA and facC-PCR testing were converted to
qualitative (positive, negative) indexes. In the case of
facC-PCR every single run was evaluated independently.
After calculating the series of sensitivity (Se) and specifi-
city (Sp) reports at every single decision threshold the
receiver operating characteristic (ROC) curve was edited
by plotting the true positive values (sensitivity values on y-
axis) versus the false positive rates (1-specificity values on
x-axis). Area under the ROC curve (AUC) was estimated
with 95 % confidence intervals (95 % CIs) and with stand-
ard errors (±SD) where values greater than 0.91 represent
excellent discriminatory accuracy, values of 0.81 - 0.9 rep-
resent good accuracy, values of 0.71 - 0.8 fair accuracy,
values of 0.61 - 0.7 poor accuracy and values of 0.5 - 0.6
represent a diagnostically not useful test. Fisher’s exact
test was used to generate two-sided P values with a P
value of < 0.05 being considered significant. Further-
more likelihood ratios (LR+, LR-) and predictive values
(PV+, PV-) were estimated.
Results
Classification of febrile episodes
Patient demographics with regard to EORTC/MSG clas-
sification are shown in Table 1.
Discriminatory power achieved by combining CT with
GM-EIA and BAL
Concordant negative GM-EIA together with thoracic CT
scans has been shown to have the highest discriminatory
power to exclude IPA as a diagnosis. The calculated PV−
proved to be high; 0.94 (17 controls, 1 case) (Fig. 1a).
When combining BAL with thoracic CT scans the calcu-
lated PV− proved to be; 0.92 (12 controls, 1 case). BAL
was performed in 77 % of all episodes. (6 cases and 15
controls). In the control group BAL excluded IPA in
93 % of the episodes (14 of 15). BAL was able to diag-
nose IPA in one case only (patient ID 10). In this case
CT failed to detect IPA (Fig. 1b).
Diagnostic performance of the biomarker assays
Performance parameters such as sensitivity (Se), specifi-
city (Sp), likelihood ratios (LR+, LR−), predictive values
(PV+, PV−) and diagnostic odds ratio (DOR) were esti-
mated for GM-EIA serology and facC-PCR by using the
current cutoff index for the gold-standard GM-EIA
(OD450/620≧0.5) and by considering a single positive PCR
run as significant for facC-PCR. Performance parameters
with and without stratification correction are shown in
Table 2.
Data on CBT
On completion of combined biomarker testing categorical
data; median, mean, standard deviations (±SD) were calcu-
lated for GM screening (GM-EIA) and for the nucleic acid
based diagnostic method (facC-PCR). Data are shown
in Fig. 2.
Sample concordance
Sample concordance was assessed between the two classi-
fiers; Platelia Aspergillus GM-EIA and facC-PCR showing
a fair agreement generating an observed ratio of 70.13 %
(agreement; 54 of 77) and a kappa statistic of 0.258 (95 %
Fig. 1 Representation of the discriminatory power of Aspergillus GM-EIA (a) and BAL (b) when combining these with chest CT. a CT+-GM+; episodes
proved to be positive when testing both by CT and Aspergillus GM-EIA, CT+-GM−; episodes proved to be positive when scanning by CT and negative
when testing by Aspergillus GM-EIA, CT−-GM+; episodes proved to be negative when scanning by CT and positive when testing by Aspergillus GM-EIA,
PCR−-GM−; episodes proved to be negative when testing by both CT and Aspergillus GM-EIA. Black symbols represent controls while red symbols
represent cases. Contoured symbols represent episodes with ceased fever, while shaded symbols represent episodes with present or recurrent fever
refractory to broad spectrum antibiotic treatment. Small sized symbols represent children. Numbers denote patient ID numbers. b CT+-BAL+; episodes
proved to be positive when testing both by CT scanning and BAL, CT+-BAL−; episodes proved to be positive when testing by thoracic CT and negative
when testing by BAL, CT−-BAL+; episodes proved to be negative when testing by thoracic CT and positive when testing by BAL, CT−-BAL−; episodes
proved to be negative when testing both by thoracic CT and BAL. Black colored symbols represent controls while red colored symbols represent cases.
Contoured symbols represent episodes with ceased fever, while shaded symbols represent episodes with present or recurrent fever refractory to broad
spectrum antibiotic treatment. Small sized symbols represent children. Numbers denote patient ID numbers
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confidence interval from 0.057 to 0.460). Distributions of
the positive and negative hits (77 GM-EIA OD450/620
values, 85 PCR Cq-s) were visualized by dot histogram
(Additional file 1: Figure S1).
Diagnostic accuracy
Area under the ROC curve (AUC) was estimated for
both classifiers; GM-EIA and facC-PCR. Values repre-
sent for GM-EIA a fair while for facC-PCR a good dis-
criminatory property. The area under the ROC-curve
(AUC) for GM-EIA was 0.7283 (95 % CI 0.6031-0.8535);
P value of < 0.0012 ± 0.0639 while that for the facC-PCR
was 0.8004 (95 % CI 0.6976-0.9031); P value of < 0.0001 ±
0.05243. ROC curves with the calculated AUCs are shown
in (Fig. 3).
Combined biomarker assay performance by section analysis
Testing control serum specimens with GM-EIA and
facC-PCR yielded a high specificity (96 %) (Fig. 4b). Only
two control specimens from episodes with no EORTC/
MSG evidence of IPA were false-positive when testing
with GM-EIA. GM-EIA failed to detect the presence of
Aspergillus GM antigen in 63 % of the cases and sensi-
tivity proved to be only 38 % (Fig. 4a). In the case popu-
lation facC-PCR was able to detect the presence of
Aspergillus fumigatus specific nucleic acid target
molecules in 84 % of cases by considering a single posi-
tive run from triplicate reactions as significant. Con-
versely facC-PCR failed to detect 16 % of the samples
from cases (Fig. 4a). With regard to specificity, 83 % of
control specimens were negative when tested with facC-
PCR ensuring a relatively high false-positivity rate of
17 % for PCR (Fig. 4b). Comparison analysis was done
by examining the different sections of Venn-diagrams
shown in Fig. 4. Only paired results were considered and
those that were superior in numbers (in the cases of pa-
tient ID 4 and ID 10 for the benefit of facC-PCR) were
excluded from the section analysis. In doing so we can
see that 50 % of specimens from cases were detected
only by facC-PCR but not with GM-EIA thus 8 % of
specimens from cases were missed with either of the
two methods. It is noteworthy that in 83 % of all cases
when testing control specimens (from episodes with no
EORTC/MSG evidence of IPA) both assays remained con-
sistently negative furthermore there were no false-positive
cases when testing with both methods.
Survival and mortality data
The overall mortality rate was 48.14 % (Additional file 2:
Figure S2). 13 of 27 patients died during the surveillance
period; 4 of 13 were cases (30.77 %) and 9 were controls
(69.23 %). Post mortem histology (PMH) was pursued in
53.85 % (7 of 13 patients) of fatalities. 10 of 23 people
(43.47 %) with patient ID 4, 9, 11, 14, 15, 17, 18, 19, 22,
24 (Fig. 1a) from the GM-EIA negative group and 3 of 4
people (75 %) with patient ID 7, 10, 13 from the GM-EIA
positive (Fig. 1a) group. In the case of one episode of the
latter group PMH proved to be negative (Additional file 2:
Figure S2; patient ID 10).
Stratification correction at autopsy
In two cases major discrepancies were observed between
the clinical and postmortem findings.
(i) Autopsy proved hyphal tissue invasion in only one
patient (Additional file 2: Figure S2; patient ID 4).
Interestingly this patient’s fever ceased in response
to antibiotic treatment and provided negative CT
result along with 7 consecutive negative GM-EIA
tests but generated positive PCR results in 10/11
runs (Fig. 4). This case was thus classified “possible”
and remained undiagnosed. It was only at autopsy
that this patient was confirmed to have had IPA.
The presence of fungal hyphal invasion in the lung
tissue was confirmed by PAS and H&E staining and
the episode was subsequently classified “proven”
(Additional file 3: Figure S3).
(ii) One episode (patient ID 24) was originally classified
“probable” based on persistent fever refractory to
broad spectrum antibiotic treatment, positive
Table 2 Diagnostic performance of GM-ELISA and facC-PCR when
testing serum samples
Parameter Platelia Aspergillus-EIA facC-PCR
% Se (95 % CI) 52,63 (28,90-75,51) 69,23 (48,21-85,63)
% Sp (95 % CI) 98,31 (90,88-99,72) 68,85 (55,71-80,09)
LR+ 31,05 2,22
LR- 0,48 0,45
PV+ % 90,91 48,65
PV- % 86,57 84,00
DOR (95 % CI) 64,44 (7,342-565,694) 4,974 (1,81-13,434)
% Se (95 % CI) 37,5 (17,97-57,48) 84 (65,46-93,19)
% Sp (95 % CI) 96 (87,02-99,54) 83,02 (70,19-91,91)
LR+ 9,5491 4,85
LR- 0,6651 0,21
PV+ % 89,4268 75,68
PV- % 62,9298 88,00
DOR (95 % CI) 15,33 (3,117-75,420) 28,667 (9,048-90,823)
P value P < 0,0001 P < 0,0001
Calculated diagnostic performance for Platelia Aspergillus GM-EIA and facC-PCR
at the standard cutoff OD450/620≧0.5 for GM-EIA and by considering ≧1 positive
Cq as significant/triplicate. Performance parameters calculated after stratification
corrections based on autopsy data are highlighted with bold letters. Se sensitivity,
Sp specificity, 95 % CI 95 % confidence interval, LR+ likelihood ratio positive,
LR- likelihood ratio negative, DOR, PV+ positive predictive value, PV- negative
predictive values
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thoracic CT, and one positive GM-EIA result out of
three but definite negative PCRs (9 of 9 runs). As
postmortem histology could not demonstrate fungal
involvement, episode was reclassified “possible”
(Additional file 4: Figure S4).
Discussion
The incidence of life threatening invasive fungal infec-
tions (IFI) caused by filamentous fungi is continuously
increasing [19, 20]. Aspergillus species are among the
most common human pathogens causing serious infec-
tions in severely immunocompromised patients and
those suffering from prolonged neutropenia [21, 22]. Pa-
tients with acute myeloid leukemia (AML) are consid-
ered to be at the highest risk for developing neutropenia
and consequent IFI [23]. Adequate antifungal therapy
initiated early in the course of disease could mitigate
devastating effects of IFI. Despite advances in the field of
antifungal therapy and improvements in diagnosis through
the use of rapid methods to screen for Aspergillus genus
(GM by sandwich ELISA) or species specific (nucleic acid
detection by PCR) biomarkers, estimation of the risk of
infection has remained difficult thus clinicians rely on
empirical treatment. The limitations of conventional
diagnostic methods such as cultures and radiology
Fig. 3 Diagnostic performance (receiver operating characteristic curves)
for Aspergillus GM-EIA and facC-PCR methods. ROC curve illustrating
the diagnostic performance of GM-EIA and facC-PCR at different
discriminatory thresholds by plotting true positives (sensitivity) against
false positives (1-specificty)
Fig. 2 Data on CBT in fevered neutropenia episodes at the University Hospitals of Debrecen. (✤) Neutrophil count less than 500/mm3. (✔)
persistent fever for more than 96 h, refractory to antibiotic treatment, (group I patients); (✘) lack of persistent fever more than 96 h, (group II
patients); (‡) according to European Organization for Research and Treatment of Cancer criteria. (FNE); febrile neutropenia episode. There were in
total 162 tests (mean; 2.93 ± 2.14/FNE) performed. 77 serum specimens (mean; 2.79 ± 1.89/FNE) were screened for the presence of GM antigen
and 85 PCRs (mean; 3,07 ± 2.39/FNE) were performed supported by 249 runs (mean; 9 ± 7.02/FNE) and targeting special fungal nucleic acid
marker genes (facC-PCR) of prokaryotic origin. Reporting of descriptivce statistics with mean values and standard error (±SE) are shown
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contribute to delayed treatment of disease. IPA occurs
mainly among people with prolonged neutropenia, and
only few data are available on IPA in non-neutropenic
patients [24]. Our prospective study introduces a com-
bined biomarker monitoring strategy for the manage-
ment of IPA in patient groups developing neutropenia
by using a nucleic acid based real-time diagnostic
adjunct to more established diagnostic techniques to
enable early and more accurate diagnostic decisions.
An aspergillosis surveillance group was established at
the University Hospitals of Debrecen comprising geneti-
cists, molecular biologists, microbiologists and physicians,
to assess the discriminatory power of combined biomarker
testing by considering facC-PCR results together with those
of the GM-EIA in our local patient population including
patients with different hematological malignancies. The
study was observational, thus no diagnostic or treatment
decisions were based on the study’s results. According to
our inclusion criteria patients with febrile neutropenia were
considered from the appearance of fever. FNEs underwent
combined biomarker testing by screening of sera for the
presence of GM antigenemia (GM-EIA) and the facC-PCR
with the mean duration of 3.11 ± 2.36 days.
During patient surveillance thoracic CT scans were
performed on FNEs and IPA was confirmed in 57 % (4
of 7) of cases; 3 episodes with proven and one episode
with probable IPA thus generating a low PV+ of 0.57 but
a relatively high PV− of 0.85. In one case of a patient (ID
16) with persistent fever, clinical diagnosis of invasive
mold infection (IMI) was supported by CT even though
BAL culture and GM-EIA (3/3) were consistently nega-
tive. Bronchoscopy with lavage was performed in 78 %
of episodes (20 of 27 patients), which yielded an ex-
tremely low PV+ (0.16). False positivity was observed in
only one case (patient ID 5) ensuring a high PV− (0.93).
Interestingly this patient provided misleading CT results
and gave a positive (1/3) GM-EIA result.
It was noticeable that co-analyzing the GM-EIA results
with that of CT scans (Fig. 1) provided sufficient strong
discriminatory power to exclude IPA (PV− was 0.94).
There was only one case (patient ID 4) with a fever that
ceased that proved to be false-negative with both of the
primary diagnostic methods (GM-EIA and CT). Analysis
of BAL was also negative in this case and the patient did
not receive antifungal treatment. However during the
extended follow-up period facC-PCR showed consecu-
tive positive results and a high PV+ of 0.91. In this epi-
sode we extended the biomarker surveillance period to
17 days gathering 11 facC-PCR and 7 GM-EIA samples
which gave contradictory data; 10 positive facC-PCRs
compared to 7 negative GM-EIA.
PMH was pursued in 7 cases and 2 episodes were re-
classified after autopsy (Table 2). In both cases facC-
PCR convincingly supported the presence (patient ID 4)
and the absence (patient ID 24) of Aspergillus hyphae.
By comparing our in-house facC-PCR method with GM-
Fig. 4 Venn-diagrams with section-analysis comparing the outcomes of Platelia Aspergillus GM-EIA and facC-PCR. TP true-positive, FN false-negative,
TN true-negative, FP false-positive. Cases (proven and probable IA) with positive GM-EIA and PCR results were regarded as true positive (TP) while those
with negative outcomes were considered to be false negative (FN). Controls (unclassified patients with no EORTC/MSG evidence of IA) with negative
GM-EIA and PCR results were coded to true negative (TN) and those with positive outcomes false positive (FP). a 27 of 32 (84 %) and 9 of 24 (38 %)
serum samples from cases (proven/probable) proved to be true positive (TP) when testing with facC-PCR and GM-EIA respectively. GM-EIA failed to
detect 15 of 24 and facC-PCR 5 of 32 samples. Section analysis: 8 of 24 specimens from cases (33 %) proved to be true positive (TP) with both assays
and 3 of 24 (8 %) found to be negative (FN) by both of them. There was only one specimen (4 %) of 24 that was missed by facC-PCR but not by
GM-EIA. 50 % of specimens (12 of 24) however were detected only by PCR but not with GM-EIA. b 51 of 53 (96 %) and 44 of 53 (83 %) serum
specimens from controls (unclassified patients with no evidence of IA) proved to be negative (TN) thus 2 of 53 (3,8 %) and 9 of 53 (17 %) were
undetected. There were 9 of 53 (17 %) specimens that proved to be false-positive with PCR but real-negative with GM and only 2 of 53 (4 %) that proved
to be false-positive with GM-EIA but true-negative with facC-PCR. Section analysis: 83 % of specimens (44 of 53) remained consistently negative with
both of the assays but there were none that proved to be false-positive when testing with both methods
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EIA it turned out, that sensitive PCR methods could
have the capacity to fill the gaps left behind by serology
and CT when co-analyzing their results thus generating
specific results with high PV−.
Conclusion
In this pilot-study we have shown the potential of combin-
ation testing to diagnose IPA more accurately in FNEs with
different hematological malignancies. CBT should combine
the gold-standard serology (GM-EIA) with sensitive and
specific nucleic acid based techniques (e.g. facC-PCR) from
the onset of febrile neutropenia. This study is relatively
small and carried out over a single year but the observed
disease prevalence proved to be high (25.9 %). The sensitiv-
ity of GM-EIA was found to be only 36 %, which is lagging
behind the average results found in other studies. Although
the low number of patients presents the major obstacle to
drawing strong conclusions we intend to alert clinicians
and researchers in this field to the discriminatory power of
combined biomarker testing. The CBT approach considers
the results of PCR assays together with the results of GM-
serology and radiology in clinical decision making thus
complementing the relatively low sensitivity of GM-EIA by
the more efficient nucleic acid based methods [25]. In
doing so we concluded that our patient management strat-
egy has the potential to be accurate and prompt enough,
possibly decreasing hospital expenditures and supporting
evidence-based diagnosis.
Additional files
Additional file 1: Figure S1. Dot histogram (1/A) visualizing the
distribution of the Platelia Aspergillus GM-EIA hits (OD450/620) with the
regard to patient status. Dot histogram (1/B) visualizing the distribution
of the facC-PCR hits (Cq values) with the regard to patient status. Group-
control Cq-values correspond to outcomes by testing specimens from
possible episodes while group-case Cq-values correspond to outcomes
by testing specimens from proven/probable cases.
Additional file 2: Figure S2. Representation of the data on postmortem
histology. (IA+) the presence of hyphae representative of invasive fungal
infection was confirmed by PAS or H&E staining. (IA-) the presence of
hyphae could not be confirmed by PAS or H&E staining. Black symbols
represent controls while red symbols represent cases. Contoured symbols
represent episodes where fever ceased, while shaded symbols represent
episodes with present or recurrent fever refractory to broad spectrum
antibiotic treatment. Small sized symbols represent children. Numbers
intend to denote patient ID numbers.
Additional file 3: Figure S3. Postmortem histological findings from
case ID 4 showing congestion and focal atelectasis of the lung (3A, ×10
magnification, H&E staining). Detailed evaluation underlined the Aspergillus
specific PCR assay based assumption of the presence of invasive Aspergillus
hyphae (3B). This was also supported by PAS staining (3C, ×40 magnification)
although definite identification is not possible on a morphological basis
therefore the presence of other filamentous fungi cannot be excluded.
Additional file 4: Figure S4. Gross view (4/A, ×10 magnification) and
high-power image (4/B, ×40 magnification) of the postmortem lung
specimens in case ID 24. Atelectasis with fibrinohemorrhagic exudate and
alveolar damage is clearly visible but evidence of microscopic fungal
manifestation is absent.
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